Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

AAO 2018: Non-contact Panretinal Photocoagulation for Navilas® 577s Introduced by OD-OS

OD-OS GmbH
Posted on: 24 Oct 18
AAO 2018: Non-contact Panretinal Photocoagulation for Navilas® 577s Introduced by OD-OS First retinal laser with a navigated non-contact treatment option for panretinal photocoagulation up to the far periphery. Visit AAO booth #740 for a demo of enhanced comfort for sensitive patients.

PR Newswire

IRVINE, California and TELTOW, Germany, Oct. 24, 2018

IRVINE, California and TELTOW, Germany, Oct. 24, 2018 /PRNewswire/ -- Just in time for the Annual Meeting of the American Academy of Ophthalmology (AAO 2018) in Chicago, OD-OS is launching a new widefield objective which brings non-contact panretinal photocoagulation with access to the far periphery (ora serrata) to the Navilas® 577s Laser System. The new option for peripheral treatments can further enhance compliance of sensitive patients and therefore allow for more comfortable PRP sessions.

This addition makes Navilas® the only retinal laser which allows for navigated focal and peripheral treatments (single spots and pattern) without a contact lens. The system supports digital pre-planning and computer-assisted delivery of laser spots thanks to its integrated eye tracking technology.

For a demo of navigated non-contact PRP treatment, visit OD-OS at the AAO in Chicago:

  • October 26: #44 at the AAO Retina Subspecialty Day
  • October 27-30: #740 at the AAO main exhibition

The non-contact widefield objective will become available to Navilas® 577s users at the end of this year.

Regional availability may vary.

Watch video at: www.od-os.com/prp

Here is what Navilas® users, who recently tested the non-contact widefield objective in clinical practice are saying:

Dr. Gregor Eberlein, University Clinic Augsburg, Germany: "My experience of extending comfortable non-contact treatment to the periphery was really good. It can be a great option for retinopexy and PRP treatments of patients averse to the contact lens."

Dr. Jean-Christophe Ramel, France: "The field of view of the non-contact widefield objective is really amazing. I had a perfect view of a retinal tear in the far periphery."

Dr. Stephan Deichelbohrer, St. Vincentius-Kliniken Karlsruhe, Germany: "The non-contact widefield objective allows me to apply more spots in a single session as the cornea remains clear throughout the whole procedure – also by letting the patient lean back and blink for a moment. When using a standard contact lens the image quality may degrade due to superficial staining of the cornea."

Ulrike Rahn, Clinical Project Manager at OD-OS: "This is a result from a successful collaboration with our Navilas® customers at CHI de Créteil in France that our development team has now turned into another treatment option for our Navilas® 577s Laser." 

Listen to Navilas® users at AAO:

  • Q&A sessions at OD-OS #740 on October 27/28 at 10:00 am – more at: www.od-os.com/aao2018
  • Talk by our user Dr. Jay Chhablani at Retina Subspecialty Day covering current knowledge on microsecond pulsing laser treatment (RET07, Friday, Oct 26, 11:39 am, Room: ARIE CROWN)

Media contact: Stefanie Gehrke, Director Marketing | stefanie.gehrke@od-os.com, +49(172)3808-537

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/aao-2018-non-contact-panretinal-photocoagulation-for-navilas-577s-introduced-by-od-os-300737233.html

SOURCE OD-OS GmbH

PR Newswire
www.prnewswire.com

Last updated on: 24/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.